Article Text

Download PDFPDF
Outcome of Recurrent Uterine Papillary Serous Carcinoma Treated With Platinum-Based Chemotherapy
  1. Haider Mahdi, MD,
  2. Anthony Rizzo, BA and
  3. Peter G. Rose, MD
  1. Gynecologic Oncology Division, Ob/Gyn and Women’s Health Institute, Cleveland Clinic, Cleveland, OH.
  1. Address correspondence and reprint requests to Haider Mahdi, MD, Gynecologic Oncology Division, Ob/Gyn and Women’s Health Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195. E-mail: mahdih6281@gmail.com.

Abstract

Objective The aim of this study was to estimate the outcome and response to platinum-based chemotherapy (CT) in patients with recurrent uterine papillary serous carcinoma (UPSC).

Methods Patients with recurrent UPSC from 2000 to 2012 were included retrospectively. All patients received platinum-based CT for recurrent disease. Platinum-free interval was divided into less than 6 months (platinum resistant) and 6 months or longer (platinum sensitive).

Results Twenty-two patients with recurrent UPSC were included. The median age was 66.5 years. The majority of the patients initially presented with advanced-stage disease (68%). A total of 84% (18/22) received adjuvant CT; all regimens were platinum based.

The overall response rate (RR) and stable disease were 50% and 36.4%. The mean duration of response and stable disease were 9.4 and 5.6 months. Among the platinum-sensitive group, the overall RR was 64.7% compared with 0% in the platinum-resistant group. Among the patients who received prior adjuvant platinum-based CT, the RR was 38.8% compared with 100% among those who did not receive adjuvant CT. When stratified by platinum-based regimen, those who received the platinum-taxane regimen had a higher RR compared with those who received the platinum-gemcitabine regimen (62.5% vs 20%) among those who received prior adjuvant platinum therapy. The median progression-free survival and overall survival for the entire cohort were 8.4 and 24.9 months, respectively. The median progression-free survival was significantly longer for platinum-sensitive disease compared with platinum-resistant disease (10.2 vs 3.3 months, respectively; P = 0.002). Similarly, the median overall survival was longer for platinum-sensitive disease compared with platinum-resistant disease (27.1 vs 13.7 months, respectively). However, this difference was not statistically significant (P = 0.15).

Conclusions Platinum-based CT is an active regimen in recurrent UPSC even if patients received prior adjuvant platinum CT. Platinum-free interval predicts response and outcome of platinum-based CT in recurrent setting such as in ovarian cancer. Plantinum-taxane is more active than platinum-gemcitabine in recurrent UPSC.

  • Recurrent UPSC
  • Platinum-free interval
  • Platinum-based chemotherapy
  • Response
  • Outcome

Statistics from Altmetric.com

Supplementary materials

Related Data

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.